Daily or continuous gonadorelin suppresses the HPG axis — the same mechanism as GnRH agonist castration therapy. 2–3x per week pulsatile dosing is required to maintain LH/FSH. Gonadorelin returned to Category 1 under the 2026 RFK reclassification — now widely available through compounding pharmacies with prescription.
Exceptional — 50+ years of GnRH physiology research
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is gonadorelin?
Gonadorelin is synthetic GnRH — identical in structure to the gonadotropin-releasing hormone your hypothalamus naturally produces in pulses to drive LH, FSH, and testosterone production. It's one of the most widely prescribed peptides in the men's health space, used almost universally alongside testosterone replacement therapy (TRT) to prevent the testicular atrophy and spermatogenesis suppression that TRT causes on its own.
The problem with TRT without gonadorelin is straightforward: exogenous testosterone suppresses the HPG axis via negative feedback. LH and FSH drop to near zero. The testes — deprived of LH stimulation — stop producing testosterone and begin to shrink. Sperm production ceases. For men who want to maintain testicular size, function, and fertility on TRT, something needs to maintain LH stimulation to the testes. That's gonadorelin's job: administered subcutaneously 2–3 times per week, it provides pulsatile GnRH stimulation to the pituitary, maintaining LH release, which in turn maintains testicular function.
The pulsatile/continuous distinction is the most important practical fact about gonadorelin: pulsatile = stimulating; continuous = suppressive. This is not a side effect — it's fundamental physiology established by Belchetz et al. (Science, 1978). Category 1 status under the 2026 reclassification has significantly expanded access through compounding pharmacies, making gonadorelin one of the most commonly prescribed peptides in men's health practices.
How it works
GnRH Receptor Activation — Pulsatile vs. Continuous
Gonadorelin binds GnRH receptors on anterior pituitary gonadotroph cells. In pulsatile administration: each pulse stimulates LH and FSH secretion, maintaining downstream testosterone production. In continuous administration: GnRH receptors desensitize and downregulate — LH and FSH fall, producing profound hypogonadism. This is why GnRH agonists like leuprolide are used in prostate cancer medical castration. Gonadorelin's practical use requires maintaining the pulsatile pattern (2–3x per week, not daily).
LH Maintenance During TRT and Spermatogenesis
When exogenous testosterone suppresses LH to near zero, Leydig cells lose stimulation and intratesticular testosterone falls dramatically — even though circulating testosterone is elevated. This drives testicular atrophy and impairs spermatogenesis. Pulsatile gonadorelin maintains LH pulses → Leydig cell stimulation → intratesticular testosterone → testicular volume. Gonadorelin also maintains FSH, which acts on Sertoli cells to support spermatogenesis — critical for men who want to preserve fertility potential on TRT.
HPG Axis Restoration Post-TRT
After stopping TRT, the HPG axis needs time to recover. Gonadorelin can be used during this transition to stimulate pituitary GnRH receptors and accelerate return of endogenous LH and FSH production — working at the GnRH receptor level rather than through estrogen blockade like SERMs (clomid, nolvadex). Some practitioners combine both approaches for faster HPG axis restoration.
What the research shows
HUMAN EVIDENCE
STUDYAndrologia · 2018
Gonadorelin maintains testicular volume and spermatogenesis during testosterone therapy
Habous M et al.
Prospective study in men on TRT. Gonadorelin added to TRT maintained testicular volume and sperm production. Control group on TRT alone showed significant testicular atrophy and azoospermia. Key clinical evidence for gonadorelin's TRT co-administration rationale.
Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E.
Classic foundational paper establishing that pulsatile GnRH is required for LH/FSH secretion — continuous GnRH causes GnRH receptor desensitization and axis suppression. This is why gonadorelin must be given pulsatilely (2–3x per week), not daily.
Pulsatile GnRH therapy restores LH/FSH in GnRH deficiency
Crowley WF Jr, Filicori M, Spratt DI, Santoro NF.
Landmark clinical study. Pulsatile GnRH via pump restored normal LH/FSH pulsatility and testosterone in men with GnRH deficiency. Established clinical proof of concept for pulsatile GnRH replacement. Foundational for TRT co-administration use.
✓Pulsatile gonadorelin maintains LH/FSH during TRT — clinical evidence (Habous 2018)
✓Continuous GnRH suppresses the axis — pulsatile is critical (Belchetz Science 1978)
✓GnRH receptor mechanism well-characterized — 50+ years of research
✓Spermatogenesis preservation with gonadorelin during TRT confirmed
✓Category 1 status 2026 — compounding pharmacy access restored
?UNCERTAIN
?Optimal frequency and dose alongside TRT for maximum testicular preservation
?Whether gonadorelin is superior to HCG for testicular function on TRT
?Long-term fertility outcomes after TRT + gonadorelin vs. TRT alone
?Whether gonadorelin alone meaningfully elevates testosterone in eugonadal men
What the community reports
Gonadorelin has moved from a niche TRT adjunct to one of the most discussed peptides in men's health communities — driven partly by the Category 1 reclassification making it compounding-accessible and partly by physicians specializing in men's health who now prescribe it as standard practice alongside TRT.
—Maintained testicular size on TRT — the most important practical outcome; users who add gonadorelin report no testicular atrophy vs. significant atrophy on TRT alone
—Preserved fertility potential — men on TRT but wanting children report gonadorelin as essential for maintaining spermatogenesis
—Gonadorelin vs. HCG: the dominant comparison. HCG mimics LH directly. Gonadorelin stimulates pituitary to release LH naturally. Community reports comparable testicular preservation outcomes; gonadorelin causes milder estrogen elevation
—3x per week subcutaneous is the most commonly reported protocol alongside TRT; some users do 2x per week
—Injection site reactions more common than with many peptides — rotation is important
Common misconceptions
"Gonadorelin raises testosterone directly."
REALITY
Gonadorelin stimulates LH release, which stimulates Leydig cells to produce testosterone. It doesn't directly elevate testosterone — it maintains the signaling pathway that allows the testes to do so. On TRT, this means maintaining intratesticular testosterone (important for testicular function) rather than significantly elevating total circulating testosterone.
Daily administration produces receptor desensitization and axis suppression — the mechanism behind GnRH agonist cancer treatment (medical castration). Pulsatile administration (2–3x per week) maintains receptor sensitivity and LH response. More frequent is not better.
"Gonadorelin can replace TRT."
REALITY
For men with primary hypogonadism (testicular failure), gonadorelin won't help — the testes aren't responding to LH regardless. For secondary (hypothalamic/pituitary) hypogonadism, it can stimulate LH and potentially elevate testosterone, but typically not to TRT levels without very frequent pulsatile administration.
COMPARE — HPG AXIS STIMULATION
Kisspeptin works upstream of gonadorelin — it stimulates GnRH neurons to release GnRH, rather than acting as GnRH directly. Kisspeptin activates the natural hypothalamic signaling; gonadorelin replaces the GnRH signal at the pituitary level. Both preserve HPG axis function; different points of intervention.
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
I'm starting TRT and want to preserve testicular function. How should I add gonadorelin?
Adding gonadorelin alongside TRT from day one is the right approach — testicular preservation is much easier to maintain than to restore. Here's the protocol framework and what to watch for. Standard TRT co-administration protocol: 100 mcg gonadorelin subcutaneous, 2–3 times per week. Most protocols prescribe it on the same day as TRT injection plus one or two additional days. The timing within the day doesn't matter much — what matters is the frequency. The non-negotiable: do not dose daily. Daily gonadorelin causes GnRH receptor desensitization — it paradoxically suppresses LH, not stimulates it. This is the mechanism behind leuprolide's use in prostate cancer medical castration. Pulsatile (2–3x per week) is stimulating. Daily is suppressive. Gonadorelin vs. HCG: HCG was the previous standard for testicular preservation on TRT — it mimics LH directly at the Leydig cell level. Gonadorelin stimulates the pituitary to release LH naturally. Both work. Gonadorelin causes milder estrogen elevation (HCG often requires an aromatase inhibitor alongside it). With the 2026 Category 1 reclassification, gonadorelin is the more accessible option now. Monitoring: testicular volume — self-assess monthly; any reduction vs. pre-TRT baseline warrants dose adjustment. LH and FSH bloodwork at 3 months — should be maintained above near-zero levels if gonadorelin is working. If you want fertility preservation specifically: semen analysis at 6 and 12 months. Intratesticular testosterone (which gonadorelin maintains) is required for spermatogenesis — gonadorelin should preserve this alongside TRT. Injection site: gonadorelin causes more local reactions than many peptides — abdomen, rotate sites each injection. Any specific concerns about fertility or testicular atrophy that are driving this?
CONTINUE IN THE APP
Open PepperLedger to track your gonadorelin protocol →
Free to join. No credit card. Ask the Coach about your TRT + gonadorelin protocol once you're in.
Free to join · No credit card · 23-day Pro trial included